|
Download
PDF
|
The Cardiovascular Market Outlook to 2011
Align your R&D pipeline to
maximize future market opportunity with the help of this NEW
report...
The Cardiovascular Market Outlook
to 2011 is a new report from Business Insights providing analysis
of the current and future market for cardiovascular drugs across
all major indications. Forecasts are given based on new product
launches, upcoming patent expiry dates, and ongoing clinical trials to enable
you to predict changes in the dynamics of the global
cardiovascular market.
This report offers insight into
R&D trends in the cardiovascular market, including the discontinuation of
key pipeline drugs such as Pfizer’s torcetrapib and atorvastatin,
and the development of new drug classes including Novartis’
Rasilez (aliskiren), anticipated to be the first to market direct
renin inhibitor.
Use this report to identify the
leading cardiovascular companies to 2011 and discover the
cardiovascular blockbusters of the future.
- Anti-hypertensives have been
the highest selling portion of the cardiovascular market in
2005. Norvasc was the leading anti-hypertensive drug in 2005,
with sales of $5bn, an increase of 3.9% from
2004.
- In 2006 the patents protecting
Zocor and Pravachol expired, which together with the
anticipated patent expiry of Lipitor in 2010, will result in a
flood of generic statins onto the market, heavily impacting
sales of branded drugs.
- Two key anti-hypertensives are
forecast to launch in 2007: Novartis’ Rasilez (aliskiren)
and Exforge (valsartan plus amlodipine). Exforge gained FDA
approval in December 2006 and is predicted to generate high
sales.
- Pfizer’s torcetrapib and
atorvastatin was discontinued in late 2006 due to safety
concerns. The discontinuation of torcetrapib will have an
impact on the other members of the CETP inhibitor pipeline
drugs, in particular Roche’s JTT-705.
- Pfizer is the leading global
cardiovascular company, with sales of nearly $20bn in 2005,
representing 15.6% of the cardiovascular market.
- The largest growth seen in the
cardiovascular market is from Amgen at 17.4%, with sales in
2005 of $6.4bn.
View
Table Of Contents >
|
